Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 8868267 | https://doi.org/10.1155/2021/8868267

Lei Zhang, Jie Yu, Yingying Liu, Weixing Guo, Yunlun Li, "Effect of Yishenjiangyafang on Plasma Metabolomics in Senile Spontaneously Hypertensive Rats", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 8868267, 14 pages, 2021. https://doi.org/10.1155/2021/8868267

Effect of Yishenjiangyafang on Plasma Metabolomics in Senile Spontaneously Hypertensive Rats

Academic Editor: Weicheng Hu
Received22 Sep 2020
Revised11 Mar 2021
Accepted25 Mar 2021
Published08 Apr 2021


Objectives. Yishenjiangyafang is a traditional Chinese medicine used to clinically treat hypertension. This study aimed to explore the effect of yishenjiangyafang on plasma metabolomics in senile spontaneously hypertensive rats (SHRs). Methods. Twelve 50-week-old SHR (6 males and 6 females) were randomly divided into two groups: a treatment group, in which rats were intragastrically administered with yishenjiangyafang (10.08 g kg−1·d−1), and a model group, in which all SHRs were administered the same volume of saline. Six age- and gender-matched Wistar–Kyoto (WKY) rats were used as the control group. Treatment was given for 6 days per week and lasted for 8 weeks. Systolic and diastolic blood pressures of the rats were measured with the noninvasive tail artery pressure measurement system. An ultraperformance liquid chromatography quadruple electrostatic field orbit (UPLC-Q-Exactive) was used to determine metabolite changes in the plasma of SHR rats before and after yishenjiangyafang treatment in the treatment group as well as in the model and control groups. Results. After yishenjiangyafang treatment, SHRs had significant lower blood pressure. Using UPLC-Q-Exactive, we identified 26 metabolic targets of yishenjiangyafang in aged SHRs and revealed that yishenjiangyafang targeted four major metabolic pathways, linoleic acid metabolism, glycerophospholipid metabolism, arginine and proline metabolism, and steroid hormone biosynthesis. Conclusion. Yishenjiangyafang decreases the blood pressure of SHRs at least in part through targeting of four major metabolic pathways. Our study illustrates mechanisms underlying the clinical application of yishenjiangyafang in the treatment of hypertensive patients.

1. Introduction

The prevalence of hypertension increases with age, and in aging populations worldwide, the elderly comprise a major proportion of those with hypertension [1]. Indeed, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) showed that more than 60% of individuals aged over 65 developed hypertension [2]. Moreover, the Framingham Heart Study reported that those who were free of hypertension before the age of 55 have over a 90% risk of developing hypertension during their remaining life time [3]. Indeed, the severity of hypertension and the incidence of comorbidities such as stroke and coronary heart diseases are also increasing with age [4], thus presenting great financial burdens for society and families of patients and significantly affecting the quality of life of patients. Although various treatments have been developed to manage hypertensive patients, a complete understanding of the molecular basis leading to hypertension remains an active area of research in the field.

Plasma metabolites are regarded as the “biochemical phenotype” of the overall functional state of the organism and are associated with cardiovascular diseases including hypertension [5]. For example, the plasma levels of oleic acid and myoinositol are reportedly major differential metabolites between the hypertensive patients and control subjects [6]. In addition, the EPIC Potsdam study showed that C42:4 and C44:3 of serine, glycine, and acylalkyllecithin were negatively correlated with the incidence of hypertension; that is, the higher the concentration of the abovementioned metabolites in the blood of the observed subjects, the lower the probability of hypertension within 10 years [7]. In addition, several antihypertensive drugs, including amlodipine and losartan, change plasma metabolites in hypertensive patients [8]. These findings suggest that plasma metabolites are involved in the development and progression of hypertension.

Traditional Chinese medicine has long been used to treat hypertensive patients and is effective in improving patient symptoms and quality of life and protecting target organs from hypertension-induced damage, thereby reducing the occurrence and/or delaying the progression of comorbidities [9]. However, due to the complexity of the ingredients in traditional Chinese medicine, the mechanisms causing reduction of hypertension have not been understood well.

Yishenjiangyafang, a traditional Chinese medicine, has been effectively used to treat hypertension in the clinic [10]. Yishenjiangyafang has been shown to protect against hypertension-induced kidney damage by affecting RAS in hypertensive rats [11]. However, whether yishenjiangyafang affects plasma metabolites associated with hypertension is unclear. Given that the elderly are significantly affected by hypertension, in this study, we used ultra-high-performance liquid chromatography quadruple electrostatic field orbit (UPLC-Q-Exactive), a high-resolution mass spectrometry, to study the effect of yishenjiangyafang on the plasma metabolites in senile spontaneously hypertensive rats (SHRs) before and after treatment with yishenjiangyafang. Our study illustrates metabolomics-related mechanisms underlying the application of yishenjiangyafang in the clinical treatment of hypertension.

2. Materials and Methods

2.1. Animals and Grouping

Wistar–Kyoto (WKY) rats and SHRs were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. Twelve 50-week-old SHRs (6 male and 6 female; body weight 190.46 ± 8.71 g for male and 125.38 ± 6.89 g for female) were randomly divided into two groups: a treatment group (n = 6), hereinafter referred to as “TG,” in which all SHRs were intragastrically administered with yishenjiangyafang (10.08 g kg−1·d−1) as previously described [12], and a model group, hereinafter referred to as “MG,” in which all SHRs were administered the same volume of saline. Age-matched 6 WKY rats (3 males with a mean body weight of 285.33 ± 9.82 g and 3 females with a mean body weight of 227.82 ± 9.36 g) were included in the control group (hereinafter referred to as “CG”), in which the rats were administered with the same volume of saline.

Treatment was given for 6 days per week and lasted for 8 weeks. The blood pressure and body weight of each rat were monitored every morning. All experimental animals were caged (6 per cage) and housed in a quiet breeding room at a temperature of 17 to 25°C, a humidity of 45% to 60%, and in a 12-hour light-dark cycle and were fed with standard feed and tap water. The animal experimental protocols were approved by the Ethics Committee of the hospital, laboratory animal certificate number SCXK (Beijing) 2017- 0006.

2.2. Reagents

Yishenjiangyafang (504 g/L) was provided by the Affiliated Hospital of Shandong University of Traditional Chinese Medicine (China); this prescription consisted of Astragalus membranaceus, Astragalus membranaceus, Ligustrum lucidum, Epimedium, radix Achyranthis, mistletoe, fried jujube seed, and Alisma alisma. These traditional Chinese medicines were prepared in a mixture according to a ratio of 30 : 12 : 25 : 25 : 9 : 25 : 25 : 20, respectively. Acetonitrile was purchased from Thermo Fisher (USA); methanol was purchased from Merck (USA), and formic acid was purchased from American Tedia (USA).

2.3. Blood Pressure Measurement

Systolic and diastolic blood pressures in the tail artery were measured using the noninvasive BESN-II four-channel animal tail artery pressure measurement system (Shanghai Yuyue Medical Equipment Co., Ltd., Shanghai, China). The average value was calculated from three independent measurements per rat.

2.4. Plasma Metabolomics Study

(1)Rats were fasted for 12 hours and anesthetized with intraperitoneally injected 0.3% sodium pentobarbital (1 mL/100 g). Blood was collected from the inferior vena cava, placed in a tube containing heparin for anticoagulation, allowed to stand for 1 h, and centrifuged at 3500 r·min−1 at 4°C for 10 min. The supernatant was collected and centrifuged at 10,000 rpm for 5 min at 4°C, and the plasma samples were dispensed into 1.5 mL EP tubes. After the relevant safety tests, the plasma samples were stored at −80°C for future analysis. The plasma samples were thawed and shaken at room temperature before treatment. 100 μL was taken to dissolve in 200 μL acetonitrile, swirled for 2 min to mix thoroughly, refrigerated at 4°C for 6 h, and centrifuged at 4°C for 10,000 r/min for 15 min. The supernatant was frozen at −20°C for future use.(2)Plasma samples were thawed at 4°C on the ice. An aliquot of the 100 μl plasma sample was precipitated after adding 400 μl precooled methanol, being vortexed for 1 min, and 2-chloro-L-phenylalanine (60 μg/mL) was used as an internal standard. The mixture was centrifuged at 15,000 rpm for 15 min at 4°C. The supernatant (400 μL) was placed in a 2-mL EP tube, dried with nitrogen, and then, redissolved by adding the initial mobile phase of 100 μL. Subsequently, the supernatants were transferred to LC-MS vials before the Ultrahigh Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UHPLC-QTOF/MS) analysis. To ensure data quality for metabolic profiling, pooled quality control samples were prepared by mixing 5 μL supernatant from each sample.(3)The quality control (QC) samples were inserted into the UPLC-Q-ExActive MS/MS spectral analysis detection sequence, and the principal component analysis (PCA) results were analyzed to monitor the stability and reproducibility of the method from sample pretreatment to sample detection. The QC sample was the mixed sample of all plasma samples. Before the detection of a large number of plasma samples, the QC sample was tested for two consecutive times to balance the system. Next, about 6 samples to be tested were inserted at every interval and 1 QC sample was inserted for detection. PCA analysis was performed on the obtained data matrix containing QC samples to investigate the clustering effect of QC samples in order to evaluate the reliability of data quality and the repeatability of test results.(4)An UltiMate 3000 ultraperformance liquid chromatograph (UHPLC, Thermo Scientific) was used for the HPLC analysis; a chromatographic separation was performed on a Thermo-C18 column (Hypersil GOLD aQ, 100 × 2.1 mm, 1.9 μm) with a flow rate of 0.30 ml/min, a column temperature of 45°C, an injector temperature of 15°C, and each injection volume of 6 μL. Mobile phase A comprised water containing 0.05% formic acid, and phase B was acetonitrile containing 0.05% formic acid.(5)The mass spectrometer had positive and negative ion modes which were used for mass spectrometry analysis using the Thermo Scientific Quaternary rod-electrostatic orbit (UPLC-Q-Exactive) (Q Exactive™ hybrid quadruple-Orbitrap MS, USA). The positive and negative ion mode detection conditions were ion source HESI, capillary voltage 3500 V, capillary temperature 320°C, source temperature 350°C, sheath gas 45 arb, auxiliary gas 10 arb, MS acquisition range 80–800 m/z, resolution 70,000, and S-Lens RF Level 55. Potential biomarker ions were further subjected to MS/MS detection to automatically optimize collision energy based on ion conditions.(6)The original spectral data (“.Raw” format) were obtained by analyzing the metabolic data of rat plasma samples and then converted to the “.mzXML” format recognizable by open source data processing software (XCMS software; http://metlin.scripps.edu/download/using ProteoWizard software (http://proteowizard.sourceforge.net/). XCMS was also used for peak identification, alignment, correction, and retention time correction and, finally, to generate a three-dimensional data matrix consisting of retention time, mass-to-charge ratio, and peak intensity.(7)Microsoft Excel software was used to convert the 3D data matrix into a “.CSV” format file, and MetaboAnalys v4.0 software was used for preprocessing and multivariate analysis of metabolomics data. The MetaboAnalys v4.0 data analysis module was used to provide the t-test, analysis of variance (ANOVA), Principal Component Analysis (PCA), and Partial Least Squares-Discriminant Analysis (PLS-DA) to complete the data matrix integrity test, missing value estimation, data filtering, and standardization. PCA, PLS-DA, hierarchical clustering, and other pattern recognition analysis were then carried out to examine the effect of the sample classification.(8)Differential metabolites were screened step by step. The first step used an OPLS-DA-generated S-Plot to perform preliminary screening of differential variables. The second step used a Volcano Plot for differential analysis. The third step further rescreened the data based on Variable Importance for the Projection (VIP) to exclude variables with a VIP < 1. The fourth step used the combination of Fold Change (filter the parts with FC greater than 2) and the t-test to screen the remaining different variables for markers with significant differences.(9)Based on the metabolomics data obtained, chemical information of biomarkers was entered in the KEGG database (The Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/). The pathway database metabolic pathway database was then selected, inputting the name or CAS number of the biomarker to obtain the relevant metabolic pathway(s), and thus, a collection of multiple sets of information resulting from the information of a single biomarker is obtained.

2.5. Statistical Methods

All data analyses were completed using SPSS v22.0 statistical software. All measurement data were expressed as mean ± standard deviation (SD). According to the different indicators and data types, the following statistical tests were used as needed: ANOVA, t test, and rank sum test. A value less than 0.05 was considered statistically significant.

3. Results

3.1. Comparison of Systolic and Diastolic Blood Pressure of Rats between Groups

We first compared the blood pressure between treatment, model, and control groups. As expected, the systolic and diastolic blood pressures of rats in the treatment and model groups were significantly higher than those of the control group (). In addition, before treatment, model and treatment groups had comparable systolic and diastolic blood pressures (). However, yishenjiangyafang significantly decreased both diastolic and systolic blood pressure compared with the model group (both ). As expected, yishenjiangyafang treatment significantly decreased systolic and diastolic blood pressures () (Table 1). These data confirm that SHRs have higher systolic and diastolic blood pressure and that yishenjiangyafang significantly decreases the blood pressure of SHRs.

GroupnSystolic blood pressureDiastolic blood pressure

Treatment6181.04 ± 3.92△△170.09 ± 3.79∗∗△△▲▲132.09 ± 3.33△△129.00 ± 3.18∗△△▲▲
Model6181.04 ± 3.90△△186.53 ± 3.90∗△△132.76 ± 3.55△△136.07 ± 3.92∗△△
Control6138.62 ± 3.95138.82 ± 2.29109.12 ± 3.19111.18 ± 3.42

Note. Data are presented as mean ± SD. Intragroup comparison with pretreatment using the t-test, , . Intergroup comparison by the F-test, △△ vs. control group; ▲▲ vs. model group.
3.2. UPLC-MS Analysis of Plasma Metabolic Profiles of Rats in Three Groups

We next used UPLC-MS to analyze the metabolic profiles of the plasma samples collected from rats in the treatment, model, and control groups. The total ion chromatogram (TIC) of the two models is shown in Figure 1, i.e., the positive ion model (Figure 1(a)) and negative ion model (Figure 1(b)). While TIC showed the general common metabolic characteristics of rats from these three groups, it also revealed some differences in the peaks of these three groups. Thus, the biomarkers underlying the differences in these peaks and their biological significance need to be identified.

3.3. Data Processing

The obtained UPLC-MS spectra of the positive and negative ion detection modes of each group were preprocessed with R language software to obtain a two-dimensional data matrix including m/z, RT, and its peak area. A total of 1105 variables were obtained in the positive ion data, and 1026 variables were obtained from the negative data. The data normalization module of MetaboAnalyst v4.0 was then used to normalize the raw data generated by the positive and negative ion detection.

3.4. PCA Analysis

PCA was modeled on the standardized data matrix to observe its grouping trend. In the positive ion mode, the data matrix of each group was analyzed by unsupervised PCA (Figure 2(a) and 2(b)). A total of five principal components were obtained from the PCA analysis model, and the interpretation variances from 1 to 5 were 18.5%, 17.9%, 10.2%, 8.6%, and 7%, respectively, and the cumulative interpretation sum was 62.2%, indicating good interpretation ability. The two- and three-dimensional score maps of PCA (Figures 2(c) and 2(d)) showed that the three group samples exhibited a separation trend. As an unsupervised model, PAC has a weak ability to eliminate bias caused by intragroup differences. Hence, a supervised PLS-DA model is needed to further expand the intergroup separation.

In the negative ion mode, the data matrix of each group was analyzed by unsupervised PCA (Figures 3(a) and 3(b)). The five principal components extracted by the PCA analysis model were interpreted by the variances of 1 to 5, respectively, 17.7%, 17.1%, 10.1%, 8%, and 5.6%, and the cumulative interpretation sum was 71.5%, indicating the good interpretation ability. Also, the two- and three-dimensional score maps obtained from PCA analysis (Figures 3(c) and 3(d)) showed that the samples from these three groups exhibited a separation trend. Thus, similar to the PCA analysis in the positive ion mode, the data separation between these groups must be further expanded by establishing a supervised PLS-DA model.

3.5. PLS-DA Analysis

Supervised identification was performed for the standardized data matrix of the model and the control groups, and the PLS-DA model was established to enhance the grouping and clustering effects. The positive ion detection mode (Figure 4(a)) showed that the PLS-DA analysis model generated 5 principal components, and the interpretation variances ranging from 1 to 5 were 18.4%, 7.4%, 7.5%, 6.9%, and 13.8%, respectively. PLS-DA two- and three-dimensional scores (Figures 4(b) and 4(c)) showed a significant separation between the samples from these three groups. The results of the 10-fold cross validation method (Figure 4(d), Table 2) showed that the PLS-DA model had the best effect when extracting 5 principal components with the average predictive ability Q2 of 92.07% and the prediction accuracy of 100%. These observations suggest that there may be differences in endogenous metabolic patterns between the samples from these groups.

Measure1 comps2 comps3 comps4 comps5 comps


In the negative ion mode, the PLS-DA analysis of the data matrix from each group (Figure 5(a)) showed that the first 5 interpretation variances were 20.2%, 27.2%, 6.9%, 6.3%, and 5.4%, respectively, and the PLS-DA two- and three-dimensional score maps (Figures 5(b) and 5(c)) showed that the samples from these groups exhibited significant separation. The results of the 10-fold cross validation (Figure 5(d), Table 3) showed that the PLS-DA model worked best when extracting 5 principal components with the average predictive power Q2 of 91.7% and accuracy of 100%. These findings suggest that the metabolic patterns of the three groups were different and that compared with the model group, the treatment group was closer to the control group, and the metabolic network information of the treatment group had a tendency to return to normal after yishenjiangyafang administration.

Measure1 comps2 comps3 comps4 comps5 comps


3.6. Hierarchical Clustering

The hierarchical data clustering method was used to model the standardized data matrix to further investigate the grouping and clustering effects. The hierarchical clustering results of the data matrix obtained by the positive and negative ion detection modes (Figures 6(a) and 6(b)) showed that the sample of each group was clustered into one class, which showed a clear classification trend. Moreover, after treatment with yishenjiangyafang, some samples from the treatment group could be clustered with the samples from the control group into one category. Thus, the metabolic network information from the treatment group had a tendency to return to normal after yishenjiangyafang intervention of the senile SHRs.

3.7. Screening of Differential Biomarkers

Through the metabolite analysis of the samples from these three groups, the variables with a VIP value greater than 1 were screened by PLS-DA analysis, and the retention time and mass-to-nuclear ratio were obtained. These variables were analyzed by one-way ANOVA. The variables with a value greater than 0.05 were removed, and the differential variables were used as potential biomarkers. In the positive ion mode, 56 differential metabolic markers were initially screened, while in the negative ion mode, 60 differential metabolic markers were initially screened.

3.8. Identification of Metabolic Markers

The differential metabolic markers obtained under the positive and negative ion models were introduced into the public biological databases such as HMDB, METLIN, and KEGG, and the related literatures were discussed. The compounds were analyzed and confirmed by two-stage MS, which finally identified 26 differential metabolic markers (Table 4).

No.m/zIdentification resultsPlus-minusChemical formulaKEGGHMDBTrend

1290.164177Leukotriene D4+C25H40N2O6SC05951HMDB0003080
4799.571949Cholic acid+C24H40O5C00695HMDB0000619
6348.228992LysoPC(22 : 4[7Z, 10Z, 13Z, 16Z])+C30H54NO7PC04230HMDB0010401
7389.262502PE(14 : 0/22:6[4Z, 7Z, 10Z, 13Z, 16Z, 19Z])+C41H70NO8PC00350HMDB0008847
9303.229448Linoleic acid+C18H32O2C01595HMDB0000673
13801.585965PC(15 : 0/16 : 1[9Z])+C39H76NO8PC00157HMDB0007936
14386.285977PC(16 : 1[9Z]/16 : 1[9Z])+C40H76NO8PC00157HMDB0008002
15834.61196PE(O-18 : 1[1Z]/20 : 4[5Z, 8Z, 11Z, 14Z])+C43H78NO7PC00350HMDB0005779
19176.067677Guanidoacetic acidC3H7N3O2C00581HMDB0000128
20381.228261Leukotriene B4C20H32O4C02165HMDB0001085
23230.0645655-Aminopentanoic acidC5H11NO2C00431HMDB0003355
26464.301762Glycocholic acidC26H43NO6C01921HMDB0000138

Note. Plus-minus: “+” refers to the positive ion mode, “−” refers to the negative ion mode; KEGG: the identification number of a compound in the KEGG database; HMDB: the identification number of a compound in the HMDB database; trend: the trend of biomarker levels in the treatment group compared with the model group: “↑”: rising, “↓”: decreasing.
3.9. Metabolic Pathway Analysis

The identified HMDB ID number of the differential metabolic markers was entered into the Pathway Analysis Module provided by MetaboAnalyst 4.0 software for metabolic pathway analysis. A metabolic pathway analysis summary table (Table 5) was generated, and the pathways with an influence value obtained from the pathway topology greater than 0.1 were analyzed as pathways for potential differential metabolic pathways. This approach identified four metabolic pathways: linoleic acid metabolism, glycerophospholipid metabolism, arginine and proline metabolism, and steroid hormone biosynthesis. Furthermore, the structural maps of each metabolic pathway were drawn (Figures 7(a)7(d)), and the nodes in each figure were the KEGG numbers of the biomarkers, and the red biomarkers were the metabolic markers identified in the study. Among them, each metabolic pathway was a relatively independent functional module, and the red biomarker in the pathway was a key node in the functional module.


1Linoleic acid metabolism50.1283921
2Glycerophospholipid metabolism300.7703330.275
3Arginine and proline metabolism441.129830.23297
4Steroid hormone biosynthesis701.797480.20944

Note. Total: the total number of compounds identified in the specified pathway. Hits: the exact number of matches in the uploaded marker data. Expected: the expected value of the pathway obtained by topological analysis. Impact: the influence value of the pathway obtained by topological analysis.

4. Discussion

Metabolomics is a large-scale study that analyses all low-molecular-weight metabolites in an organism or biological system during a specific physiological/pathophysiological period [13, 14]. In particular, metabolomics studies the body as a complete system and integrates whole, dynamic, comprehensive, and analytical methods. As a result, metabolomics has unique advantages for revealing the mechanisms underlying complex diseases and the metabolic mode of drugs.

In the present study, we observed that yishenjiangyafang significantly lowered the blood pressure of SHRs, as expected. We then used UPLC-Q-Exactive technology to investigate the difference in endogenous metabolic patterns between control, model, and treatment groups and identified 16 characteristic metabolic targets and four major metabolic pathways including linoleic acid metabolism, glycerophospholipid metabolism, arginine and proline metabolism, and steroid hormone biosynthesis that were specifically targeted by yishenjiangyafang.

4.1. Linoleic Acid Metabolism and Function

Linoleic acid is an essential fatty acid that binds to cholesterol. Deficiency in linoleic acid affects the metabolism of cholesterol, resulting in binding of cholesterol to unsaturated fatty acids and deposits on the arterial wall, ultimately leading to atherosclerosis [15]. Correspondingly, linoleic-acid-rich fats decrease the risk of developing atherosclerosis [16]. Another mechanism whereby linoleic acid protects cardiovascular systems is to generate prostaglandin E2 (PGE2) through a series of enzymatic reactions [17], and PGE2 is well known for its beneficial effects on blood pressure, water and salt metabolism, and inflammation through binding to four prostaglandin E receptors present on the cell membrane [18].

In the present study, we found that yishenjiangyafang significantly increased the plasma level of linoleic acid in elderly SHRs, which may be one of the mechanisms by which yishenjiangyafang ameliorates hypertension. It will be interesting to determine whether elderly SHRs treated with yishenjiangyafang also have increased levels of circulating PGE2.

4.2. Glycerophospholipid Metabolism and Function

While glycerophospholipid is a fundamental component of membranes, increased levels harm the cell membrane. For instance, glycerophospholipid-linked endothelial cell damage reduces production of nitric oxide, resulting in heightened smooth-muscle contraction and high blood pressure [19]. Phosphatidylcholine, one such glycerophospholipid, plays an important role in the metabolic process of hypertension, since phosphatidylcholine can be catalytically decomposed by different types of enzyme PLA, producing arachidonic acid and lysophosphatidylcholine, both of which mediate inflammation [20]. It should be noted that elevated inflammatory lipids such as lysophosphatidylcholine and long-chain fatty acids induce endothelial dysfunction, causing hypertension [21].

This study showed that the increased levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and lysophosphatidylcholine (LPC) in aged SHRs were ameliorated by yishenjiangyafang, thus providing another molecular basis underlying the blood pressure decrease by yishenjiangyafang.

4.3. Arginine and Proline Metabolism and Function

L-arginine is a precursor of endothelial NO, and NO is an endogenous flaccid factor produced by NO synthase and exhibits potent vasodilatory and peripheral resistance-reducing activity [22]. In addition, guanidoacetic acid can be synthesized from L-arginine and is a precursor of creatine, the latter of which has a variety of physiological functions including stimulating insulin release, neuromodulation, regulating the metabolism of arginine, and mediating the oxidative state of cells [23]. In addition, ornithine is a basic amino acid which is formed by the decomposition of arginine into alkali or arginase and is associated with urea production as a part of the urea cycle [24].

In the present study, we found that yishenjiangyafang significantly increased the plasma levels of L-arginine, thioglycolic acid, and ornithine in aged SHRs. Thus, we speculate that elevated circulating levels of L-arginine and ornithine are one of the mechanisms by which Yishenjiangyafang reduces hypertension.

4.4. Steroid Hormone Biosynthesis

Glucocorticoid is an important hormone regulating the metabolism of a variety of substances including sugar, protein, and fat, and it plays an important role in regulating growth, development, metabolism, and the immune system. For the cardiovascular system, glucocorticoid regulates blood pressure by mediating cardiac output, the level of vascular reactivity, and the relaxation of vascular smooth muscle [25]. A previous prospective study showed that the total testosterone levels are inversely associated with the risk of hypertension in the population and that low concentrations of testosterone could serve as a biological indicator for assessing cardiovascular risk [26]. Both physiological doses of testosterone and dihydrotestosterone can upregulate the expression level of NO synthase to promote phosphorylation and increase the synthesis and release of NO in endothelial cells [27], thereby exerting its role in relaxing blood vessels and regulating intravascular balance.

We found that the levels of androsterone, pregnenolone, rostenedione, and testosterone in older SHR were significantly upregulated by yishenjiangyafang treatment, thus raising the possibility that changes in the levels of glucocorticoid are involved in yishenjiangyafang-promoted reduction in blood pressure. We noted that Yishenjiangyafang also reduced the circulating levels of corxolone and dihydrocortisol, two more forms of glucocorticoid in SHRs. However, how these changes affect the blood pressure remains to be elucidated.

5. Conclusions

In summary, in the present study, we used UPLC-Q-Exactive technology to obtain 26 characteristic metabolic targets of yishenjiangyafang in aged SHRs, and we finally identified four metabolic pathways that were regulated by yishenjiangyafang. Our study confirmed that Yishen Jiangyan decoction can exert antihypertensive effects by regulating linoleic acid metabolism, glycerol phospholipid metabolism, arginine and proline metabolism, steroid hormone biosynthesis, and other key metabolic targets in metabolic pathways in SHR rats. Thus, Yishen Jiangyan decoction has been demonstrated clinically for the treatment of hypertension.

Although this study initially constructed the characteristic metabolic network of SHR rats from the perspective of metabolomics, it revealed the pathophysiological mechanism of senile hypertension. However, the analysis of markers is mostly isolated, it is difficult to reflect the systemic changes of senile hypertension, and its exact mechanism needs to be further studied by the way of multiomics integration.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval

The experimental protocol of our study was performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Affiliated Hospital of Shandong University of Traditional Chinese Medicine.


Lei Zhang and Jie Yu are the co-first authors.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


This study was supported in part by the following grants: Ph.D. Fund of the Natural Science Foundation of Shandong Province (No. ZR2017BH091), National Natural Science Foundation of China (No. 81974561), China Postdoctoral Science Foundation (No. 2017M612342), Shandong Provincial Natural Science Foundation Doctoral Fund (No.ZR2019BH033), Shandong Provincial Health Science and Technology Association Science and Technology Project (No. SDBJKT20170080), Shandong Traditional Chinese Medicine Science and Technology Development Project (2017-048), and Integrative Medicine Funded by the Special Project of Cardiovascular Taishan Scholars.


  1. N. Lionakis, D. Mendrinos, E. Sanidas, G. Favatas, and M. Georgopoulou, “Hypertension in the elderly,” World Journal of Cardiology, vol. 4, no. 5, pp. 135–147, 2012. View at: Publisher Site | Google Scholar
  2. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 Report,” Jama, vol. 289, no. 19, pp. 2560–2572, 2003. View at: Publisher Site | Google Scholar
  3. D. Levy, M. G. Larson, R. S. Vasan, W. B. Kannel, and K. K. Ho, “The progression from hypertension to congestive heart failure,” JAMA: The Journal of the American Medical Association, vol. 275, no. 20, pp. 1557–1562, 1996. View at: Publisher Site | Google Scholar
  4. T. W. Buford, “Hypertension and aging,” Ageing Research Reviews, vol. 26, pp. 96–111, 2016. View at: Publisher Site | Google Scholar
  5. D. Mozaffarian, “The microbiome, plasma metabolites, dietary habits, and cardiovascular risk unravelling their interplay,” Circulation Research, vol. 124, no. 12, pp. 1695-1696, 2019. View at: Publisher Site | Google Scholar
  6. M. Yang, Z. Yu, S. Deng et al., “A targeted metabolomics MRM-MS study on identifying potential hypertension biomarkers in human plasma and evaluating acupuncture effects,” Scientific Reports, vol. 6, Article ID 25871, 2016. View at: Publisher Site | Google Scholar
  7. S. Dietrich, A. Floegel, C. Weikert et al., “Identification of serum metabolites associated with incident hypertension in the european prospective investigation into cancer and nutrition-potsdam study,” Hypertension, vol. 68, no. 2, pp. 471–477, 2016. View at: Publisher Site | Google Scholar
  8. T. P. Hiltunen, J. M. Rimpela, R. P. Mohney, S. M. Stirdivant, and K. K. Kontula, “Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension,” PLoS One, vol. 12, no. 11, Article ID e0187729, 2017. View at: Publisher Site | Google Scholar
  9. J. Wang and X. Xiong, “Evidence-based Chinese medicine for hypertension,” Evid Based Complement Alternat Med, vol. 2013, Article ID 978398, 12 pages, 2013. View at: Publisher Site | Google Scholar
  10. J. Yu, L. Yao, and M. Yu, “Kidney-tonifying formula combined with amlodipine treatment clinical observation of senile hypertension,” Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, vol. 13, no. 18, pp. 2086-2087, 2015. View at: Google Scholar
  11. M. L. Chen, W. J. Liu, C. Y. Wang et al., “[Effects of yishenjiangyafang on blood pressure and protecting renal function in RPH rats],” Zhongguo Zhong Yao Za Zhi, vol. 28, no. 8, pp. 746–751, 2003. View at: Google Scholar
  12. X. L. Tu, J. P. Sun, Y. P. Qiu, and W. X. Guo, “Experimental study on the effect of tonifying kidney qi on collagen content in spontaneously hypertensive rats,” Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, vol. 7, no. 11, pp. 1309-1310, 2009. View at: Google Scholar
  13. S. Rochfort, “Metabolomics reviewed: a new “omics” platform technology for systems biology and implications for natural products research,” Journal of Natural Products, vol. 68, no. 12, pp. 1813–1820, 2005. View at: Publisher Site | Google Scholar
  14. M. Wang, R.-J. A. N. Lamers, H. A. A. J. Korthout et al., “Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology,” Phytotherapy Research, vol. 19, no. 3, pp. 173–182, 2005. View at: Publisher Site | Google Scholar
  15. N. Katajavuori, O. Salminen, K. Vuorensola, H. Huhtala, P. Vuorela, and J. Hirvonen, “Competence-based pharmacy education in the university of helsinki,” Pharmacy (Basel), vol. 5, no. 2, 2017. View at: Google Scholar
  16. M. Sato, K. Shibata, R. Nomura, D. Kawamoto, R. Nagamine, and K. Imaizumi, “Linoleic acid-rich fats reduce atherosclerosis development beyond its oxidative and inflammatory stress-increasing effect in apolipoprotein E-deficient mice in comparison with saturated fatty acid-rich fats,” British Journal of Nutrition, vol. 94, no. 6, pp. 896–901, 2005. View at: Publisher Site | Google Scholar
  17. T. L. Kaduce, A. A. Spector, and R. S. Bar, “Linoleic acid metabolism and prostaglandin production by cultured bovine pulmonary artery endothelial cells,” Arteriosclerosis: An Official Journal of the American Heart Association, Inc., vol. 2, no. 5, pp. 380–389, 1982. View at: Publisher Site | Google Scholar
  18. I. Dey, M. Lejeune, and K. Chadee, “Prostaglandin E2 receptor distribution and function in the gastrointestinal tract,” British Journal of Pharmacology, vol. 149, no. 6, pp. 611–623, 2006. View at: Publisher Site | Google Scholar
  19. T. Róg and I. Vattulainen, “Cholesterol, sphingolipids, and glycolipids: what do we know about their role in raft-like membranes?” Chemistry and Physics of Lipids, vol. 184, pp. 82–104, 2014. View at: Publisher Site | Google Scholar
  20. M. Hermansson, K. Hokynar, and P. Somerharju, “Mechanisms of glycerophospholipid homeostasis in mammalian cells,” Progress in Lipid Research, vol. 50, no. 3, pp. 240–257, 2011. View at: Publisher Site | Google Scholar
  21. M.-L. N. Huynh, V. A. Fadok, and P. M. Henson, “Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 41–50, 2002. View at: Publisher Site | Google Scholar
  22. R. M. McAllister, S. C. Newcomer, and M. H. Laughlin, “Vascular nitric oxide: effects of exercise training in animals,” Applied Physiology, Nutrition, and Metabolism, vol. 33, no. 1, pp. 173–178, 2008. View at: Publisher Site | Google Scholar
  23. M. Wyss and R. Kaddurah-Daouk, “Creatine and creatinine metabolism,” Physiological Reviews, vol. 80, no. 3, pp. 1107–1213, 2000. View at: Publisher Site | Google Scholar
  24. B. Mouillé, V. Robert, and F. Blachier, “Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 287, no. 2, pp. G344–G351, 2004. View at: Publisher Site | Google Scholar
  25. Y. M. Xiao, “Study on the clinical application of glucocorticoids,” Journal of North Pharmacy, vol. 16, no. 3, pp. 172-173, 2019. View at: Google Scholar
  26. S. Torkler, H. Wallaschofski, S. E. Baumeister et al., “Inverse association between total testosterone concentrations, incident hypertension and blood pressure,” The Aging Male, vol. 14, no. 3, pp. 176–182, 2011. View at: Publisher Site | Google Scholar
  27. L. Goglia, V. Tosi, A. M. Sanchez et al., “Endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivo,” Molecular Human Reproduction, vol. 16, no. 10, pp. 761–769, 2010. View at: Publisher Site | Google Scholar

Copyright © 2021 Lei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.